All T Cells articles – Page 3
-
NewsNew research shows way to bypass immunotherapy resistance
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
-
NewsComputational pipeline for personalised cancer vaccine design
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
-
Article’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings. ...
-
NewsType 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
-
NewsProstate cancer: delaying resistance to hormone therapy
Researchers have developed a new form of immunotherapy that could provide a longer life expectancy to men with prostate cancer.
-
NewsThe role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
-
NewsRare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
-
NewsDeveloping a globally-applicable HIV cure
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
News
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
-
ArticleTreating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
-
ArticleImproving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
-
ArticleUtilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
-
News
New TEC organoid model to study thymus function
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
-
NewsHow tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
-
NewsExplaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
-
NewsFOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
-
NewsEliminating the HIV virus from infected cells with CRISPR-Cas
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
-
NewsNew insights about the influence of STAP-1 on immune cell activation
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
-
NewsNew insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.